Correction To: Prolonged Stable Disease in a Uveal Melanoma Patient With Germline MBD4 Nonsense Mutation Treated With Pembrolizumab and Ipilimumab

Immunogenetics - Germany
doi 10.1007/s00251-019-01120-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Panhypopituitarism in Metastatic Melanoma Patient Treated With Ipilimumab and Pembrolizumab

Journal of Cutaneous Immunology and Allergy
2019English

Severe Hemophagocytic Lymphohistiocytosis in a Melanoma Patient Treated With Ipilimumab + Nivolumab

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2018English

Scalp Melanoma Treated With Ipilimumab in Elderly Patient: A Complete Response to Treatment—Case Report

Journal of Pharmacy and Pharmacology
2017English

Fatal Myocarditis and Rhabdomyositis in a Patient With Stage IV Melanoma Treated With Combined Ipilimumab and Nivolumab

Current Oncology
Oncology
2019English

Prolonged Benefit From Ipilimumab Correlates With Improved Outcomes From Subsequent Pembrolizumab

Cancer immunology research
Cancer ResearchImmunology
2016English

Pneumocystis Jirovecii Pneumonia in a Patient With Melanoma Treated With Infliximab and Corticosteroids for Ipilimumab-Associated Colitis

Global Dermatology
2016English

Adjuvant Ipilimumab in High-Risk Uveal Melanoma

Cancers
Cancer ResearchOncology
2019English

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient With Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome

Case Reports in Oncological Medicine
Oncology
2018English

Response to Pembrolizumab in a Heavily Treated Patient With Metastatic Ovarian Carcinosarcoma

Gynecologic Oncology Research and Practice
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy